Design, synthesis and biological evaluation of hybrid bioisoster derivatives of N-acylhydrazone and furoxan groups with potential and selective anti-Trypanosoma cruzi activity

European Journal of Medicinal Chemistry

Volumn 82, Issue , 2014, Pages 418-425

  Massarico Serafim, Ricardo Augusto ^a   Gonçalves, José Eduardo ^a   De Souza, Felipe Pereira ^a   De Melo Loureiro, Ana Paula ^a   Storpirtis, Silvia ^a   Krogh, Renata ^a   Andricopulo, Adriano Defini ^a   Dias, Luiz Carlos ^b   Ferreira, Elizabeth Igne ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Anti Trypanosomacruzi compounds; Bioisosters; Furoxan derivatives; Molecular hybrids; N acylhydrazone derivatives; Nitric oxide donor groups

Indexed keywords

3 METHYL 4 [[2 (2 PHENYLACETYL)HYDRAZONO]METHYL] 1,2,5 OXADIAZOLE 2 OXIDE; 3 METHYL 4 [[2 (3 NITROBENZOYL)HYDRAZONO]METHYL] 1,2,5 OXADIAZOLE 2 OXIDE; 3 METHYL 4 [[2 (4 NITROBENZOYL)HYDRAZONO]METHYL] 1,2,5 OXADIAZOLE 2 OXIDE; 3 METHYL 4 [[2 [2 (PHENYLAMINO)BENZOYL]HYDRAZONO]METHYL] 1,2,5 OXADIAZOLE 2 OXIDE; 3 [(2 BENZOYLHYDRAZONO)METHYL] 4 PHENYL 1,2,5 OXADIAZOLE 2 OXIDE; 3 [[2 (3 NITROBENZOYL)HYDRAZONO]METHYL] 4 PHENYL 1,2,5 OXADIAZOLE 2 OXIDE; 3 [[2 (4 BROMOBENZOYL)HYDRAZONO]METHYL] 4 PHENYL 1,2,5 OXADIAZOLE 2 OXIDE; 3 [[2 (4 CHLOROBENZOYL)HYDRAZONO]METHYL] 4 PHENYL 1,2,5 OXADIAZOLE 2 OXIDE; 3 [[2 (4 NITROBENZOYL)HYDRAZONO]METHYL] 4 PHENYL 1,2,5 OXADIAZOLE 2 OXIDE; 3 [[2 (FURAN 2 CARBONYL)HYDRAZONO]METHYL] 4 PHENYL 1,2,5 OXADIAZOLE 2 OXIDE; 4 PHENYL 3 [[2 (2 PHENYLACETYL)HYDRAZONO]METHYL] 1,2,5 OXADIAZOLE 2 OXIDE; 4 [(2 BENZOYLHYDRAZONO)METHYL] 3 METHYL 1,2,5 OXADIAZOLE 2 OXIDE; 4 [[2 (4 BROMOBENZOYL)HYDRAZONO]METHYL] 3 METHYL 1,2,5 OXADIAZOLE 2 OXIDE; 4 [[2 (4 CHLOROBENZOYL)HYDRAZONO]METHYL] 3 METHYL 1,2,5 OXADIAZOLE 2 OXIDE; 4 [[2 (FURAN 2 CARBONYL)HYDRAZONO]METHYL] 3 METHYL 1,2,5 OXADIAZOLE 2 OXIDE; ANTITRYPANOSOMAL AGENT; CRUZAIN INHIBITOR; CYSTEINE PROTEINASE INHIBITOR; FUROXAN DERIVATIVE; HYDRAZONE DERIVATIVE; N ACYLHYDRAZONE DERIVATIVE; NITRIC OXIDE; UNCLASSIFIED DRUG; 1,2,5-OXADIAZOLE 2-OXIDE; ANTINEOPLASTIC AGENT; OXADIAZOLE DERIVATIVE;

AMASTIGOTE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CACO 2 CELL LINE; CANCER CELL LINE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL MEMBRANE PERMEABILITY; COLON CARCINOMA; CYTOTOXICITY; CYTOTOXICITY ASSAY; DIASTEREOISOMER; DRUG ABSORPTION; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY; TRYPANOSOMA CRUZI; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HEPG2 CELL LINE; SYNTHESIS;

ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HEP G2 CELLS; HUMANS; HYDRAZONES; MOLECULAR STRUCTURE; OXADIAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84902507567     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.05.077     Document Type: Article

References (33)

1. J.R. Coura, and J.C.P. Dias Epidemiology, control and surveillance of Chagas disease - 100 years after its discovery Mem. Inst. Oswaldo Cruz 104 2009 31 40
2. R.J. Anis, R. Anis, and J.A. Marin-Neto Chagas disease Lancet 375 2010 1388 1402
3. World Health Organization, WHO (2013). http://www.who.int/mediacentre/ factsheets/fs340/en/index.html.
4. J. Gascon, C. Bern, and M.J. Pinazo Chagas disease in Spain, the United States and other non-endemic countries Acta Trop. 115 2010 22 27
5. M.C.P. Nunes, W. Dones, C.A. Montillo, J.J. Encina, and A.L. Ribeiro Chagas disease: an overview of clinical and epidemiological aspects J. A. Coll. Cardiol. 62 2013 767 776
6. L.C. Dias, M.A. Dessoy, J.N.S. Silva, O.H. Thiemann, G. Oliva, and A.D. Andricopulo Quimioterapia da doença de Chagas: estado da arte e perspectivas no desenvolvimento de novos fármacos Quim. Nova 32 2009 2444 2457
7. R.M. Alves, R.P. Thomaz, E.A. Almeida, J.S. Wanderley, and M.E. Guariento Chagas disease and egeing: the coexistence of other chronic disease with Chagas disease in elderly patients Rev. Soc. Bras. Med. Trop. 42 2009 622 628
8. E.J. Barreiro, and C.A.M. Fraga Química Medicinal: as bases moleculares da ação dos fármacos second ed. 2008 Artmed Porto Alegre 271 277 343-345
9. L.M. Lima, and E.J. Barreiro Bioisosterism: a useful strategy for molecular modification and drug design Curr. Med. Chem. 12 2005 23 49
10. C. Viegas-Junior, A. Danuello, V.S. Bolzani, E.J. Barreiro, and C.A.M. Fraga Molecular hybridization: a useful tool in the design of new drug prototypes Curr. Med. Chem. 14 2007 1829 1852
11. R.A.M. Serafim, M.C. Primi, G.H.G. Trossini, and E.I. Ferreira Nitric oxide: state of the art in drug design Curr. Med. Chem. 19 2012 385 405
12. H. Cerecetto, and M. González Anti-T. cruzi agents: our experience in the evaluation of more than five hundred compounds Mini-Rev. Med. Chem. 8 2008 1355 1383
13. J.J.N. Silva, P.M.M. Guedes, A. Zottis, T.L. Balliano, F.O.N. Silva, L.G.F. Lopes, J. Ellena, G. Oliva, A.D. Andricopulo, D.W. Franco, and J.S. Silva Novel ruthenium complexesas potential drugs for Chagas's disease: enzyme inhibition and in vitro/in vivo trypanocidal activity Br. J. Pharmacol. 160 2010 260 269
14. L.R. Brunet Nitric oxide in parasitic infections Int. Immunopharmacol. 1 2001 1457 1467
15. N.C. Romeiro, G. Aguirre, P. Hernandez, M. Gomzalez, H. Cerecetto, I. Aldana, S. Perez-Silanes, A. Monge, E.J. Barreiro, and L.M. Lima Synthesis, trypanocidal activity and docking studies of novel quinaxoline-N-acylhydrazones, designed as cruzain inhibitors candidates Bioorg. Med. Chem. 17 2009 641 652
16. D.R.M. Moreira, A.C.L. Leite, R.R. Santos, and M.B.P. Soares Approaches for the development of new anti-Trypanosoma cruzi agents Curr. Drugs Targets 10 2009 212 231
17. M.E. McGrath, A.E. Eakin, J.C. Engel, J.H. McKerrow, C.S. Craik, and R.J. Fletterick The crystal structure of cruzain: a therapeutic target for Chagas' disease J. Mol. Biol. 247 1995 251 259
18. W.A.S. Judice, M.H.S. Cezari, A.P.C.A. Lima, J. Scharfstein, J.R. Chagas, I.L.S. Tersariol, M.A. Juliano, and L. Juliano Comparison of the specificity, stability and individual rate constants with respective activation parameters for the peptidase activity of cruzipain and its recombinant form, cruzain, from Trypanosoma cruzi Eur. J. Biochem. 268 2001 6578 6586
19. S.R. Wilkinson, C. Bot, J.M. Kelly, and B.S. Hall Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives Curr. Med. Chem. 11 2011 2072 2084
20. MarvinView 5.4.0. - Free License 1998-2010 ChemAxon Ltd
21. P. Hernandez, R. Rojas, R.H. Gilman, M. Sauvain, L.M. Lima, E.J. Barreiro, M. Gonzalez, and H. Cerecetto Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates Eur. J. Med. Chem. 59 2013 64 74
22. S. Storpirtis, J.E. Gonçalves, C. Chiann, and M.N. Gai Biofarmacotécnica-série Ciências Farmacêuticas Guanab. Koogan 2009 204 211
23. J. Souza, L.Z. Benet, Y. Huang, and S. Storpirtis Comparison of bidirectional Lamavudine and Zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers J. Pharm. Sci. 98 2009 4413 4419
24. H.V. Chavda, C.N. Patel, and I.S. Anand Biopharmaceutical classification system Syst. Rev. Pharm. 1 2010 62 69
25. P.C. Huber, C.H. Maruiama, and W.P. Almeida Glicoproteína-P, resistência a múltiplas drogas (MDR) e relação estrutura-atividade de moduladores Quim. Nova 33 2010 2148 2154
26. R. Fruttero, B. Ferrarotti, A. Serafino, D. Stiloa, and A. Gasco Unsummetrically substituted furoxans, Part 11, methylfuroxancarbaldehydes J. Heterocycl. Chem. 26 1989 1345 1347
27. A.M. Gasco, R. Fruttero, G. Sorba, and A. Gasco Unsymmetrically substituted furoxans, Part XIII, phenylfuroxancarbaldehydes and related compounds Liebigs Ann. Chem. 1991 1211 1213
28. R.S. Braman, and S.A. Hendrix Nanogram nitrite and nitrate determination in enviromental and biological materials by vanadium(III) reduction with chemiluminescence detection Anal. Chem. 61 1989 2715 2718
29. Castegnaro et al. Food Addit. Contam. 4 1978 37 43
30. A.E. Eakin, A.A. Mills, G. Harth, J.H. McKerrow, and C.S. Craik The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi J. Biol. Chem. 267 1992 7411 7420
31. R. Li, G.L. Kenyon, F.E. Cohen, X. Chen, B. Gong, J.N. Dominguez, E. Davidson, G. Kurzban, R.E. Miller, E.O. Nuzum, P.J. Rosenthal, and J.H. McKerrow In vitro antimalarial activity of chacones and their derivatives J. Med. Chem. 38 1995 5031 5037
32. D.M. Borchardt, A. Mascarello, L.D. Chiaradia, R.J. Nunes, G. Oliva, R.A. Yunes, and A.D. Andricopulo Biochemical evaluation of a series of synthetic chalcone and hydrazide derivatives as novel inhibitors of cruzain from Trypanosoma cruzi J. Braz. Chem. Soc. 21 2010 142 150
33. J.E. Gonçalves, M.B. Fernandes, C. Chiann, M.N. Gai, J. Souza, and S. Storpirtis Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells Biopharm. Drug. Dispos. 33 2012 316 323